Aliskiren: A novel, orally active renin inhibitor

Systematic Reviews in Pharmacy

Volumn 1, Issue 1, 2010, Pages 93-98

  Mohamed Saleem, T S ^a   Jain, A ^b   Tarani, P ^b   Ravi, V ^b   Gauthaman, K ^b  

^a ANNAMACHARYA COLLEGE OF PHARMACY   (India)

^b HIMALAYAN PHARMACY INSTITUTE   (India)

Author keywords

Aliskiren; Hypertension; Renin inhibitors; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; AMLODIPINE; ATENOLOL; BENAZEPRILAT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CIMETIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; MEVINOLIN; PLACEBO; RAMIPRIL; VALSARTAN; WARFARIN;

ALBUMINURIA; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BACKACHE; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EDEMA; FACE EDEMA; FATIGUE; GASTROINTESTINAL DISEASE; GLOMERULOSCLEROSIS; HAND EDEMA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IC 50; KIDNEY ARTERY STENOSIS; LARYNGOPHARYNGITIS; LIP EDEMA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORBIDITY; MORTALITY; NEPHROLITHIASIS; NONHUMAN; PHARMACODYNAMICS; PHARYNGITIS; PREGNANCY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TONGUE EDEMA; WHOLE BODY EDEMA;

EID: 78650502099     PISSN: 09758453     EISSN: 09762779     Source Type: Journal    
DOI: 10.4103/0975-8453.59518     Document Type: Review

References (56)

1. O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007;49:276-84. (Pubitemid 46143002)
2. Atlas SA. The Renin-Angiotensin Aldosterone System: Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13:S9-20.
3. Piepho RW, Beal J. An overview of antihypertensive therapy in the 20 th century. J Clin Pharmacol 2000;40:967-77.
4. Pool JL. Direct renin inhibition: Focus on aliskiren. J Manag Care Pharm 2007;13:21-33.
5. Ian AR. Vasoactive peptides. In: Katzung BG, editor. Basic and clinical pharmacology. 10 th ed. USA: McGraw Hill; 2007. p. 280.
6. Buczko W, Hermanowicz JM. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep 2008;60:623-31.
7. Kelly DJ, Wilkinson-Berka JL, Gilbert RE. Renin inhibition: New potential for an old therapeutic target. Hypertension 2005;46:569-76.
8. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. The renin angiotensin system in the development of cardiovascular disease: Role of aliskiren in risk reduction. Vascular Health Risk Manage 2008;4:971-81.
9. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, et al. Structure-based design of aliskiren: A novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705. (Pubitemid 36976519)
10. Campbell DJ. Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension 2008;51:e27-8.
11. Allikmets K. Aliskiren: An orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension. Vasc Health Risk Manag 2007;3:809-15.
12. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368:1449-56. (Pubitemid 44573444)
13. Danser AH. (Pro)renin receptors: Are they biologically relevant? Curr Opin Nephrol Hypertens 2009;18:74-8.
14. Azizi M. Renin inhibition. Curr Opin Nephrol Hypertens 2006;15:505-10.
15. Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007;35:1418-28. (Pubitemid 47121784)
16. de Gasparo M, Cumin F, Nussberger J, Guyenne TT, Wood JM, Menard J. Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br J Clin Pharmacol 1989;27:587-96. (Pubitemid 19145091)
17. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren: A novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005;23:417-26. (Pubitemid 40279646)
18. Gaddam KK, Oparil S. Renin inhibition: Should it supplant ACE inhibitors and ARBS in high risk patients? Curr Opin Nephrol Hypertens 2008;17:484-90.
19. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, et al. Aliskiren, A human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76. (Pubitemid 41376839)
20. Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006;1:221-8.
21. Azizi M, Mnard J, Bissery A, Guyenne TT, Bura-Rivire A, Vaidyanathan S, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15:3126-33. (Pubitemid 39578845)
22. Cada DJ, Levien T, Baker DE. Aliskiren. Hosp Pharmacy 2007;42:737-49.
23. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007;50:2398-404. (Pubitemid 47512400)
24. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: Comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008;51:1306-11. (Pubitemid 351555942)
25. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-8. (Pubitemid 40354519)
26. Weir M, Bush C, Zhang J, Keffe D, Satlin A. Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with HTN. Eur Heart J 2006;27:229.
27. Serebruany VL, Malinin A, Barsness G, Vahabi J, Atar D. Effects of aliskiren: A renin inhibitor, on biomarkers of platelet activity, coagulation and fibrinolysis in subjects with multiple risk factors for vascular disease. J Hum Hypertens 2008;22:303-10. (Pubitemid 351575086)
28. Azizi M. Direct renin inhibition: Clinical pharmacology. J Mol Med 2008;86:647-54.
29. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008;73:1419-25. (Pubitemid 351770494)
30. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137-43. (Pubitemid 37549068)
31. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev 2008;8:CD007066.
32. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension: A Cochrane systematic review. J Hum Hypertens 2009;23:495-502.
33. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119:530-7.
34. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: A 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009;119:417-25.
35. Nickenig G, Simanenkov V, Lembo G, Rodriguez P, Salko T, Ritter S, et al. Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Press 2008;17:31-40.
36. Yarows SA, Oparil S, Patel S, Fang H, Zhang J. Aliskiren and valsartan in stage 2 hypertension: Subgroup analysis of a randomized, double-blind study. Adv Ther 2008;25:1288-302.
37. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006;29:997-1005. (Pubitemid 46206586)
38. Krop M, Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK, et al. Aliskiren accumulates in Renin secretory granules and binds plasma prorenin. Hypertension 2008;52:1076-83.
39. Dietz R, Dechend R, Yu CM, Bheda M, Ford J, Prescott MF, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1. J Renin Angiotensin Aldosterone Syst 2008;9:163-75.
40. Westermann D, Riad A, Lettau O, Roks A, Savvatis K, Becher PM, et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008;52:1068-75.
41. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 2008;57:3297-306.
42. Schernthaner G. Dual inhibition with losartan and aliskiren: A promising therapeutic option for type 2 diabetic nephropathy? Nat Clin Pract Nephrol 2008;4:656-7.
43. Mitchell J, Oh B, Herron J, Chung J, Khan M, Satilin A, et al. Once-daily aliskiren provides effective, smooth 24-h blood pressure control in patients with hypertension. J Clin Hypertens 2006;8:A93.
44. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49:1047-55. (Pubitemid 351664315)
45. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1164-5.
46. Oparil S, Yarows SA, Patel S, Zhang J, Satlin A. Dual inhibition of the renin system by aliskiren and valsartan. Lancet 2007;370:1126-7. (Pubitemid 47464577)
47. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Zhang J, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-26. (Pubitemid 44885684)
48. Azizi M, Mnard J, Bissery A, Guyene TT, Bura-Rivire A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol 2007;2:947-55.
49. McMurray JJV, Pitt B, Latini R, Maggioni Ap, Solomon SD, Lewsey J, et al. for the Aliskiren Observation of Heart Failure Treatment, I: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.
50. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. Nat Clin Pract Nephrol 2008;4:656-7.
51. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design. Nephrol Dial Transplant 2009;24:1663-71.
52. Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med 2008;358:2503-5. (Pubitemid 351793025)
53. Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram G, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190-8. (Pubitemid 351166266)
54. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial. J Hypertens 2008;26:589-99.
55. Sanoski CA. Aliskiren: An oral direct Renin inhibitor for the treatment of hypertension. Pharmacotherapy 2009;29:193-212.
56. Cheng JW. Aliskiren: Renin inhibitor for hypertension management. Clin Ther 2008;30:31-47. (Pubitemid 351834725)